Post-implementation Review of the Human Medicines Regulations 2012 (MLX 391)
Read the full outcome
Detail of outcome
The main conclusion of the review was that on balance the 2012 Regulations represent a sound consolidation of fragmented and complex medicines legislation in one place, and in a simplified form to improve the coherence of the regulatory framework. The report contains four recommendations for some areas where further work is required.
Original consultation
Consultation description
We want to know what you think
We would appreciate your help in understanding the impact of the 2012 Regulations. In particular, the aspects of the 2012 Regulations that, in our view, introduced the most significant changes.
These include:
-
the Pharmacovigilance Directive (Directive 2010/84/EU (amending Directive 2001/83/EC) (Section 1 of the questionnaire)
-
cross Border Prescriptions (Section 2 of the questionnaire)
-
the repeal of Section 10(7) of the Medicines Act 1968 on Pharmacy wholesale dealing (Section 3 of the questionnaire)
Please answer those sections of the questionnaire on the above changes that are relevant to you. In addition, we encourage all respondents to answer the general questions on the 2012 Regulations in Section 4 of the questionnaire.
Ways to respond
Tell us your views using the on-line version of the questionnaire.
Alternatively, please tell us your views by completing the MS Word version of the questionnaire (see Annex B in the documents section above). Information on where to submit your completed questionnaire is shown at the bottom of the questionnaire.
This consultation closes at 23:45 on Thursday 6 July 2017.
Documents
Updates to this page
Published 15 June 2017Last updated 5 December 2017 + show all updates
-
Detail of outcome and attached report.
-
First published.